{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:22:30Z","timestamp":1790904150338,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015338","name":"National Cancer Institute Cancer Moonshot","doi-asserted-by":"publisher","award":["1U01CA232486"],"award-info":[{"award-number":["1U01CA232486"]}],"id":[{"id":"10.13039\/100015338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Children Cancer Free Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002736","name":"Citizens United for Research in Epilepsy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U01CA243072"],"award-info":[{"award-number":["1U01CA243072"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children&apos;s Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcped.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EJC Paediatric Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejcped.2025.100304","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:18:28Z","timestamp":1750940308000},"page":"100304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-1662","authenticated-orcid":false,"given":"Sarah K.","family":"Tasian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejcped.2025.100304_bib1","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-#","article-title":"The Philadelphia chromosome translocation. A paradigm for understanding leukemia","volume":"65","author":"Rowley","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib2","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28543","article-title":"How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults","volume":"67","author":"Slayton","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib4","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib6","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"van der Veer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib9","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1 -like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejcped.2025.100304_bib10","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib12","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib13","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2017.06.012","article-title":"BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside","volume":"82","author":"Boer","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib15","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study","volume":"8","author":"den Boer","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"145","author":"Tran","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.70037","article-title":"FIP1L1::PDGFRA fusion in a pediatric patient presenting with B-cell lymphoblastic leukemia","volume":"64","author":"Nunn","year":"2025","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib18","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-023-01843-x","article-title":"Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL","volume":"37","author":"Sadras","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41698-023-00485-7","article-title":"Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia","volume":"7","author":"Miyazaki","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejcped.2025.100304_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/bloodadvances.2021006076","article-title":"SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia","volume":"6","author":"Brown","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib24","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/leu.2017.166","article-title":"Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis","volume":"32","author":"Welsh","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib26","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood.2023023120","article-title":"Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain","volume":"143","author":"van Outersterp","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30313","article-title":"The prognostic value of IKZF1(plus) in B-cell progenitor acute lymphoblastic leukemia: results from the EORTC 58951 trial","volume":"70","author":"Kicinski","year":"2023","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib30","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1182\/blood-2022-162159","article-title":"IKZF1 Deletions are markers of treatment resistance in adult Ph-negative B-cell acute lymphoblastic leukemia patients treated within the ongoing risk-adapted pethema LAL19 trial","volume":"140","author":"Ribera","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2023021752","article-title":"Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL","volume":"143","author":"Bastian","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib32","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","article-title":"Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia","volume":"55","author":"Kim","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejcped.2025.100304_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000967","article-title":"ABL-class genomic breakpoint Q-PCR: a patient-specific approach for MRD monitoring in acute lymphoblastic leukemia","volume":"7","author":"van Outersterp","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejcped.2025.100304_bib34","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/10428194.2024.2396046","article-title":"IKZF1 in acute lymphoblastic leukemia: the rise before the fall?","volume":"65","author":"\u00d8stergaard","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejcped.2025.100304_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023023152","article-title":"How I treat adult Ph+ ALL","volume":"145","author":"Chiaretti","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/hematology.2024000532","article-title":"Ph+ ALL: new approaches for upfront therapy","volume":"2024","author":"Luskin","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ejcped.2025.100304_bib37","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024776","article-title":"Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy","volume":"144","author":"Eadie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/leu.2013.324","article-title":"RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D\/CSF1R fusion responsive to imatinib","volume":"28","author":"Lilljebj\u00f6rn","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib40","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2009-05-218560","article-title":"Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib44","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib45","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib47","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib48","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/blood-2006-04-014514","article-title":"NUP214-ABL1 in adult T-ALL: the GMALL study group experience","volume":"108","author":"Burmeister","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2013.088674","article-title":"NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins","volume":"99","author":"Kim De","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejcped.2025.100304_bib50","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41588-018-0195-8","article-title":"Integrative detection and analysis of structural variation in cancer genomes","volume":"50","author":"Dixon","year":"2018","journal-title":"Nat. Genet"},{"key":"10.1016\/j.ejcped.2025.100304_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.26487","article-title":"Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping","volume":"97","author":"Rack","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00504","article-title":"Improved gene fusion detection in childhood cancer diagnostics using RNA Sequencing","author":"Hehir-Kwa","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"9","key":"10.1016\/j.ejcped.2025.100304_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00788","article-title":"Challenging conventional diagnostic methods by comprehensive molecular diagnostics: a nationwide prospective comparison in children with aLL","author":"Boer","year":"2025","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib54","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13000-016-0541-z","article-title":"Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients","volume":"11","author":"Akhter","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ejcped.2025.100304_bib56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1541-7786.MCR-17-0569","article-title":"Targeted next-generation sequencing for detecting MLL gene fusions in leukemia","volume":"16","author":"Afrin","year":"2018","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.ejcped.2025.100304_bib57","first-page":"13","article-title":"Feasibility to use whole-genome sequencing as a sole diagnostic method to detect genomic aberrations in pediatric B-cell acute lymphoblastic leukemia","author":"Rezayee","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib58","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2022008992","article-title":"Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia","volume":"7","author":"Leongamornlert","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cancergen.2023.01.002","article-title":"Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid\/lymphoid neoplasms with eosinophilia in children","volume":"272-273","author":"Berking","year":"2023","journal-title":"Cancer Genet."},{"key":"10.1016\/j.ejcped.2025.100304_bib60","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","article-title":"Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines","volume":"38","author":"van der Velden","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib61","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib62","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1182\/blood-2024-203064","article-title":"ABL-class fusion gene induced pediatric CML presenting As ALL","volume":"144","author":"Hoogerbrugge","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib63","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41416-022-01806-6","article-title":"Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions","volume":"127","author":"Venn","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib64","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib65","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejcped.2025.100304_bib66","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cncr.31099","article-title":"Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the Children's Oncology Group study AALL1131","volume":"124","author":"Salzer","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib67","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: children's oncology group study AALL1131","volume":"38","author":"Salzer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib68","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2023-190495","article-title":"Feasibility and outcome of post-induction therapy incorporating dasatinib for patients with newly diagnosed ABL-class fusion B-lymphoblastic leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131","volume":"142","author":"Salzer","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib69","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib70","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejcped.2025.100304_bib71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2019.09.004","article-title":"Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study","volume":"122","author":"Testi","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","author":"Moorman","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib73","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib74","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib76","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib77","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib78","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib79","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023023120","article-title":"Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain","author":"van Outersterp","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib80","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib81","unstructured":"Gupta S., Rau R.E., Kairalla J.A., Rabin K.R., Wang C., Angiolillo A.L., et al. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2024."},{"key":"10.1016\/j.ejcped.2025.100304_bib82","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib83","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","author":"Hodder","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib84","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2023-174973","article-title":"Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-lineage acute lymphoblastic leukemia. final results of the phase II gimema LAL2317 Trial","volume":"142","author":"Chiaretti","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib85","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/blood-2023-177847","article-title":"Exploring the heterogeneity of response to blinatumomab in high-risk philadelphia-negative B-cell precursor acute lymphoblastic leukemia: an analysis from the QUEST sub-study of the graall-2014\/B trial","volume":"142","author":"Boissel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib86","doi-asserted-by":"crossref","first-page":"E379","DOI":"10.1002\/ajh.26281","article-title":"Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed\/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study","volume":"96","author":"Jabbour","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib87","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib89","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejcped.2025.100304_bib90","article-title":"Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL","author":"Zhao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib91","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","article-title":"Blinatumomab + ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"62","author":"Couturier","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejcped.2025.100304_bib92","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejcped.2025.100304_bib93","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejcped.2025.100304_bib94","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: Phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-Cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib95","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2020.38.15_suppl.7512","article-title":"Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R\/R PH+ ALL or CML in lymphoid blast phase (CML LBP)","volume":"38","author":"Jain","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib96","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2019-126940","article-title":"Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed\/Refractory (R\/R) Acute Lymphoblastic Leukemia (ALL)","volume":"134","author":"Jabbour","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib97","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib98","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib99","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib100","article-title":"Concomitant use of a dual ABL\/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL","author":"Leonard","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib101","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib102","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib103","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","author":"Laetsch","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib104","first-page":"21","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.ejcped.2025.100304_bib105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib106","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-023-02010-y","article-title":"Preclinical development of 1B7\/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL","volume":"37","author":"Tian","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib107","article-title":"Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia","author":"Balestra","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib108","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib109","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for Adult Philadelphia-Positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2012.09039.x","article-title":"Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study","volume":"157","author":"Chang","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib111","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","article-title":"PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib112","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.261354","article-title":"The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment","author":"Tran","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejcped.2025.100304_bib113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16338","article-title":"Experience with ponatinib in paediatric patients with leukaemia","volume":"189","author":"Rossoff","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib115","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","article-title":"Olverembatinib treatment in pediatric patients with relapsed philadelphia-chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejcped.2025.100304_bib116","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib117","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-Positive ALL","author":"Foa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib118","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejcped.2025.100304_bib119","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib120","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib121","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib122","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejcped.2025.100304_bib123","doi-asserted-by":"crossref","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejcped.2025.100304_bib124","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Aric\u00f2","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib125","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","article-title":"Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005","volume":"28","author":"Aric\u00f2","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib126","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/leu.2009.261","article-title":"Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group","volume":"24","author":"Salzer","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejcped.2025.100304_bib127","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a children's Oncology Group Study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib128","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib129","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2025.100304_bib130","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib131","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00707","article-title":"Philadelphia-like genetic rearrangements in adults with B-Cell ALL: refractoriness to chemotherapy and response to tyrosine kinase inhibitor in ABL class rearrangements","author":"Senapati","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejcped.2025.100304_bib132","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib133","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2025.100304_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35750","article-title":"Results of cancer and leukemia group B 10102 (Alliance), a phase 1\/2 study","volume":"131","author":"Luskin","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ejcped.2025.100304_bib135","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","article-title":"Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial","volume":"7","author":"Bassan","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2025.100304_bib136","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3324\/haematol.2015.124941","article-title":"BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG\/Erasmus MC and COG\/St. Jude signatures","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"}],"container-title":["EJC Paediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772610X25000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772610X25000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:08:37Z","timestamp":1778933317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772610X25000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":136,"alternative-id":["S2772610X25000923"],"URL":"https:\/\/doi.org\/10.1016\/j.ejcped.2025.100304","relation":{},"ISSN":["2772-610X"],"issn-type":[{"value":"2772-610X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents","name":"articletitle","label":"Article Title"},{"value":"EJC Paediatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejcped.2025.100304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100304"}}